Alkermes has released long term data for its OX2R agonist which could face two other drugs of the same mechanism of action on the market.

Alkermes plc ALKS reported positive interim results from its ongoing long-term extension (LTE) study of investigational oral ...

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results.

In the first quarter of 2026, Alkermes reported a narrower loss than expected and stronger-than-anticipated revenue, helped by higher sales of Vivitrol, Aristada, Lybalvi, and newly acquired Lumryz, ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Instead of the garden-variety symphony music favored by most pharma companies before entering a conference call, Alkermes selected Fleetwood Mac’s breakup anthem “Go Your Own Way.” It was a clever way ...

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was ...

Marketing drugs for mental illness is a unique challenge in pharma, and Alkermes is navigating COVID, stigma and a major generics market to get its new drug Lybalvi to patients. Lybalvi is a ...

Alkermes plc (NASDAQ:ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56. The company reported sales of $617.40 million, 124% higher than the $276.22 ...

Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales ...

Alkermes has a portfolio of commercialized neuroscience products and a pipeline that spans both neuroscience and cancer. The drugmaker is now exploring the possibility of splitting off its cancer ...

Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2). Narcolepsy type ...